儿童心脏骤停治疗性低温试验中3个月与12个月神经行为结局的关系
该研究比较THAPCA-OH和THAPCA-IH两项试验中儿童心脏骤停后3个月与12个月神经行为结局。研究对象为2009-2015年纳入的2天至<18岁儿童,干预为两种目标温度管理(低温32.0-34.0°C;常温36.0-37.5°C)。222例合格幸存者中204例有3个月和12个月VABS-II和PCPC数据(THAPCA-OH 82例,THAPCA-IH 122例)。THAPCA-OH较THAPCA-IH骤停前残疾显著更少、12个月骤停后损伤显著更重;3个月与12个月VABS-II评分相关性在THAPCA-OH为r=0.95、THAPCA-IH为r=0.72,THAPCA-IH较低(p≤0.001)。两队列3个月VABS-II和PCPC分类结局预测12个月良好VABS-II结局敏感性≥70%,但THAPCA-IH特异性(68-89%)低于THAPCA-OH(≥95%);两队列12个月诊断准确率均≥80%。作者认为未来纳入相似队列的儿童心脏骤停临床试验可考虑整合3个月神经行为结局指标。
要点
- 在THAPCA-OH和THAPCA-IH幸存者中,3个月VABS-II和PCPC分类结局预测12个月良好VABS-II结局的敏感性均≥70%。
- THAPCA-IH的3个月预测特异性为68-89%,低于THAPCA-OH的≥95%,提示住院骤停后早期结局预测需谨慎。
- 3个月与12个月VABS-II评分相关性在THAPCA-OH为r=0.95、THAPCA-IH为r=0.72,THAPCA-IH相关性较低(p≤0.001)。
- 两队列12个月VABS-II和PCPC诊断准确率均≥80%,作者认为未来相似队列试验可考虑纳入3个月神经行为结局指标。
- THAPCA-OH较THAPCA-IH骤停前残疾显著更少、12个月骤停后损伤显著更重(基于VABS-II和PCPC)。
适用人群与场景
- THAPCA-OH和THAPCA-IH试验纳入的儿童,年龄2天至<18岁,2009-2015年入组。
- 主要结局分析纳入无显著骤停前神经发育缺陷的儿童。
- 3个月和12个月VABS-II和PCPC数据可获得的222例合格幸存者中204例(THAPCA-OH 82例,THAPCA-IH 122例)。
诊断标准与关键阈值
- 12个月良好结局定义为幸存者VABS-II≥70。
- VABS-II人群均值=100,标准差=15。
- 神经行为结局采用Vineland Adaptive Behavior Scales第二版(VABS-II)和儿科脑功能分类(PCPC)量表评估。
处置流程与药物剂量
- THAPCA试验评估两种目标温度管理干预:低温32.0-34.0°C;常温36.0-37.5°C。
研究设计与关键结果
- 研究类型为对THAPCA-OH和THAPCA-IH试验数据的比较分析;204例幸存者有3个月和12个月VABS-II和PCPC数据(THAPCA-OH 82例,THAPCA-IH 122例)。
- THAPCA-OH较THAPCA-IH骤停前残疾显著更少、12个月骤停后损伤显著更重(基于VABS-II和PCPC)。
- 3个月与12个月VABS-II评分相关性:THAPCA-OH r=0.95,THAPCA-IH r=0.72,THAPCA-IH较低(p≤0.001)。
- 在骤停时<1岁的儿童中,两时间点间相关性较低但仍显著(p<0.001)。
- 两队列3个月VABS-II和PCPC分类结局预测12个月良好VABS-II结局的敏感性≥70%;特异性THAPCA-IH为68-89%,THAPCA-OH≥95%。
- 两队列12个月VABS-II和PCPC诊断准确率均≥80%。
证据类型、等级与局限
- 证据类型:对THAPCA-OH和THAPCA-IH两项试验数据的比较分析。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为,在纳入相似队列的未来儿童心脏骤停临床试验中,可考虑整合3个月神经行为结局测量。
- 在THAPCA-IH幸存者中,3个月VABS-II和PCPC分类结局预测12个月良好VABS-II结局的特异性为68-89%,低于THAPCA-OH的≥95%。
指南或共识出处
- THAPCA-OH和THAPCA-IH试验(Therapeutic Hypothermia After Pediatric Cardiac Arrest Out-Of-Hospital and In-Hospital trials)。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「红旗征与不能漏的情况」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
AIM: To inform design aspects of future trials by comparing 3 and 12-month neurobehavioural outcomes in children enrolled in Therapeutic Hypothermia After Pediatric Cardiac Arrest Out-Of-Hospital and In-Hospital (THAPCA-OH, THAPCA-IH) trials.
METHODS: The THAPCA trials evaluated two targeted temperature management interventions (hypothermia, 32.0-34.0 °C; normothermia, 36.0-37.5 °C). Children, aged 2 days to <18 years, were enrolled from 2009-2015. Three and 12-month post-cardiac arrest (CA) outcomes included the Vineland Adaptive Behavior Scales, Second Edition (VABS-II) (population mean = 100, SD = 15) and the pediatric cerebral performance category (PCPC) scale. Children without significant pre-existing neurodevelopmental deficits were included in primary outcome analyses. Among survivors, favorable 12-month outcome was defined as VABS-II ≥ 70.
RESULTS: VABS-II and PCPC were available at 3 and 12 months in 204 of 222 eligible survivors (THAPCA-OH, n = 82; THAPCA-IH, n = 122). Relative to THAPCA-IH, THAPCA-OH had significantly less pre-CA disability and significantly greater 12-month CA impairment, based on both VABS-II and PCPC. Correlations between 3 and 12-month VABS-II scores were strong for THAPCA-OH (r = 0.95) and THAPCA-IH (r = 0.72), and lower (p ≤ 0.001) in THAPCA-IH. Between time-points correlations were lower, but still significant in children <1 year at CA (p < 0.001). In both cohorts, 3-month VABS-II and PCPC categorical outcomes had high sensitivity (≥70%) for predicting favorable 12-month VABS-II outcomes, but specificity was lower for THAPCA-IH (68-89%) relative to THAPCA-OH (≥95%). Overall, 12-month diagnostic accuracy was ≥80% for both VABS-II and PCPC in both cohorts.
CONCLUSIONS: In future paediatric cardiac arrest clinical trials that enroll similar cohorts, integration of 3-month neurobehavioral outcome measures should be considered.
参考来源
- Slomine BS, Silverstein FS, Page K, et al. Relationships between three and twelve month outcomes in children enrolled in the therapeutic hypothermia after pediatric cardiac arrest trials. Resuscitation. 2019. PMID: 30922934. doi:10.1016/j.resuscitation.2019.03.020
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。